Patents Examined by Lynn A. Bristol
  • Patent number: 11117936
    Abstract: A chimeric antigen receptor is disclosed that includes: (a) an extracellular high affinity streptavidin;(b) a hinge domain from CD8; (c) a CD28 transmembrane domain; (d) an intracellular 4-1BB and/or CD28 signaling domain; and (e) an intracellular CD3 zeta signaling domain, wherein (a)-(e) are in N-terminal to C-terminal order. Nucleic acids encoding this chimeric antigen receptor, and T and natural killer (NK) cells transformed with this chimeric antigen receptor are also disclosed. The use of this chimeric antigen receptor for the treatment of tumors is also disclosed.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: September 14, 2021
    Assignee: University of Pittsburg—Of the Commonwealth System of Higher Education
    Inventor: Jason Lohmueller
  • Patent number: 11111297
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: September 7, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • Patent number: 11103579
    Abstract: Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist in combination with a DR4 or DR5 agonist.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 31, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Bryan Barnhart, Maria N. Jure-Kunkel
  • Patent number: 11091536
    Abstract: Polypeptides with biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human heavy and light chain variable domains (VHs and VLs), are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHS and VLs may be subjected to DNA shuffling to select for improved biophysical properties.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: August 17, 2021
    Assignee: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventor: Jamshid Tanha
  • Patent number: 11091554
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 17, 2021
    Assignee: Medlmmune, LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Patent number: 11083785
    Abstract: This disclosure relates to agents that bind and neutralize the inhibitory activity of Siglec-10 in lymphocytes, notably by inhibiting the binding of Siglec-10 to its sialic acid ligands on target cells, notably tumor cells. Such agents can be used for the treatment of cancers.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 10, 2021
    Assignee: INNATE PHARMA
    Inventors: Stephanie Cornen, Laurent Gauthier, Benjamin Rossi, Nicolai Wagtmann
  • Patent number: 11072644
    Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: July 27, 2021
    Assignees: Allogene Therapeutics, Inc., Cellectis
    Inventors: Arvind Rajpal, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
  • Patent number: 11066475
    Abstract: Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: July 20, 2021
    Assignees: Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
    Inventors: Blythe D. Sather, Eric L. Smith, Rupesh Amin, Aye Chen, Kimberly Harrington, Collin Hauskins, Erik Hess, Cyr De Imus, Jon Jones, Audrey Olshefsky, Stefan Ponko, Ruth Salmon, Semih Tareen, Rebecca Wu, Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons, Mariana Cota Stirner, Melissa Works
  • Patent number: 11066483
    Abstract: By replacing the antigen-binding domain, the present inventors discovered novel polypeptide complexes that retain BiTE's strong anti-tumor activity and excellent safety properties, as well as have long half-life in blood and can damage various different target cells.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: July 20, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Junichi Nezu, Takahiro Ishiguro, Atsushi Narita, Akihisa Sakamoto, Yumiko Kawai, Tomoyuki Igawa, Taichi Kuramochi
  • Patent number: 11059911
    Abstract: The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: July 13, 2021
    Assignee: UCB Biopharma SRL
    Inventors: David Paul Humphreys, Shirley Jane Peters
  • Patent number: 11058752
    Abstract: The described invention provides a tumor cell vaccine comprising genetically modified tumor cell line of a particular tumor type that stably expresses high levels of two or more immunomodulators. According to some embodiments, an immunogenic amount of the tumor cell line variants may be selected for concomitant expression of two or more of recombinant membrane expressed IgG1, CD40L, TNF-alpha, as well as membrane and soluble forms of GM-CSF, and Flt-3L peptides that are effective to elicit an anti-tumor immune response compared to the parent unmodified tumor cell line as measured in vitro by a one-way mixed lymphocyte tumor reaction assay using human peripheral blood mononuclear cells and the genetically modified allogeneic cell vaccine candidate.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: July 13, 2021
    Assignee: ALLOPLEX BIOTHERAPEUTICS
    Inventor: Frank Borriello
  • Patent number: 11059909
    Abstract: Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: July 13, 2021
    Assignee: UMC UTRECHT HOLDING B.V.
    Inventors: Jeanette Henrica Wilhelmina Leusen, Johannes Gerardus Maria Evers, Geert Jan Van Tetering
  • Patent number: 11046951
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: June 29, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • Patent number: 11045547
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 29, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Rene De Waal Malefyt, Laurence Fayadat-Dilman, Linda Liang
  • Patent number: 11034764
    Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: June 15, 2021
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Yanan Guo, Xiaodong Cheng, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni
  • Patent number: 11033636
    Abstract: The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: June 15, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
  • Patent number: 11028183
    Abstract: This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: June 8, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Nadine Tuaillon, Ezio Bonvini
  • Patent number: 11008386
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: May 18, 2021
    Assignee: Rinat Neuroscience Corp.
    Inventors: Jaume Pons, Arnon Rosenthal
  • Patent number: 11001632
    Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: May 11, 2021
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Yanan Guo, Xiaodong Cheng, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni
  • Patent number: 11001635
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: May 11, 2021
    Assignee: Gensun Biopharma Inc.
    Inventors: Jackie Sheng, Bo Liu, Margaret Karow